• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail - Product Image

Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail

  • Published: December 2012
  • Region: Global
  • 72 Pages
  • GBI Research

Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail

Summary

Leading business intelligence provider, GBI Research, has released its latest research report, entitled: “Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail”. The report provides insights into the liver cancer therapeutics market in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan, with market forecasts until 2018. It provides in-depth analysis of the major marketed products, as well as insights into the liver cancer therapeutics R&D pipeline. The report also gives in-depth analysis of the unmet needs, drivers and barriers that affect the markets in these countries. Additionally, it discusses the global pipeline for all the liver cancer molecules across various stages of development.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI READ MORE >

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Liver Cancer Therapeutics Market to 2018 - Introduction

3 Liver Cancer Therapeutics Market to 2018 - Overview
3.1 Introduction
3.1.1 Benign Tumor
3.1.2 Primary Liver Cancer
3.1.3 Secondary Liver Cancer
3.2 Symptoms
3.3 Diagnosis
3.3.1 Laboratory Tests
3.3.2 Imaging Tests
3.3.3 Others
3.4 Treatment Options
3.4.1 Surgery
3.4.2 Non-surgical
3.4.3 General Treatment Algorithm
3.4.4 Treatment by Stage
3.4.5 New Technologies in Treatment

4 Liver Cancer Therapeutics Market to 2018 - Market Characterization and Forecasts
4.1 Revenue
4.2 Annual Cost of Therapy
4.3 Marketed Products
4.3.1 Nexavar
4.3.2 Miripla
4.4 Treatment Usage Pattern
4.4.1 Prevalence Population
4.4.2 Diagnosed Population
4.4.3 Prescription Population
4.5 Drivers and Barriers of Liver Cancer Therapeutics Market
4.5.1 Drivers
4.5.2 Barriers

5 Liver Cancer Therapeutics Market to 2018 - Geographical Landscape
5.1 US
5.1.1 Introduction
5.1.2 Revenue
5.1.3 Cost of Therapy
5.1.4 Treatment Usage Pattern
5.2 Top Five European Countries
5.2.1 Introduction
5.2.2 Revenue
5.2.3 Cost of Therapy
5.2.4 Treatment Usage Pattern
5.3 Japan
5.3.1 Introduction
5.3.2 Revenue
5.3.3 Cost of Therapy
5.3.4 Treatment Usage Pattern

6 Liver Cancer Therapeutics Market to 2018 - Pipeline Analysis
6.1 Introduction
6.2 R&D Product Pipeline by Stage of Development
6.2.1 Phase III
6.2.2 Phase II/III
6.2.3 Phase II
6.2.4 Phase I/II
6.2.5 Phase I
6.2.6 Pre-Clinical
6.2.7 Discovery
6.3 Profiles of Promising Molecules
6.3.1 PrevOnco
6.3.2 Ramucirumab
6.3.3 ThermoDox
6.3.4 Afinitor

7 Liver Cancer Therapeutics Market to 2018 - Competitive Landscape
7.1 Bayer
7.2 Dainippon Sumitomo Pharma

8 Liver Cancer Therapeutics Market to 2018 - Strategic Consolidations
8.1 Introduction
8.2 Deals by Geography
8.3 Deals by Year
8.4 Mergers and Acquisition Deals
8.4.1 Overview
8.4.2 Profiles of Major M&A Deals
8.5 Licensing Agreements
8.5.1 Overview
8.5.2 Profiles of Major Licensing Agreements
8.6 Co-Development Agreements
8.6.1 Overview
8.6.2 Profiles of Major Co-Development Agreements

9 Liver Cancer Therapeutics Market to 2018 - Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Bibliography
9.4 Research Methodology
9.4.1 Coverage
9.4.2 Secondary Research
9.4.3 Primary Research
9.5 Therapeutic Landscape
9.5.2 Market Size by Geography
9.6 Geographical Landscape
9.7 Pipeline Analysis
9.8 Competitive Landscape
9.8.1 Expert Panel Validation
9.9 Contact Us
9.10 Disclaimer

1.1 List of Tables

Table 1: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue ($m), 2004-2011
Table 2: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts ($m), 2011-2018
Table 3: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue by Geography ($m), 2004-2011
Table 4: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts by Geography ($m), 2011-2018
Table 5: Liver Cancer Therapeutics Market, Top Seven Markets, Annual Cost of Therapy ($), 2004-2011
Table 6: Liver Cancer Therapeutics Market, Top Seven Markets, Annual Cost of Therapy ($), 2011-2018
Table 7: Liver Cancer Therapeutics Market to 2018, Nexavar, Clinical Trial Results
Table 8: Liver Cancer Therapeutics Market, Nexavar, Adverse Reactions Reported in Clinical Trial
Table 9: Liver Cancer Therapeutics Market, Nexavar, Approval History
Table 10: Liver Cancer Therapeutics Market, Top Seven Markets, Treatment Usage Pattern (‘000), 2004-2011
Table 11: Liver Cancer Therapeutics Market, Top Seven Markets, Treatment Usage Pattern (‘000), 2011-2018
Table 12: Liver Cancer Therapeutics Market, US, Revenue ($m), 2004-2011
Table 13: Liver Cancer Therapeutics Market, US, Revenue Forecasts ($m), 2011-2018
Table 14: Liver Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2004-2011
Table 15: Liver Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2011-2018
Table 16: Liver Cancer Therapeutics Market, US, Treatment Usage Pattern (‘000), 2004-2011
Table 17: Liver Cancer Therapeutics Market, US, Treatment Usage Pattern (‘000), 2011-2018
Table 18: Liver Cancer Therapeutics Market, Top Five European Countries, Revenue ($m), 2004-2011
Table 19: Liver Cancer Therapeutics Market, Top Five European Countries, Revenue Forecast ($m), 2011-2018
Table 20: Liver Cancer Therapeutics Market to 2018, Top Five European Countries, Annual Cost of Therapy ($), 2004-2011
Table 21: Liver Cancer Therapeutics Market to 2018, Top Five European Countries, Annual Cost of Therapy ($), 2011-2018
Table 22: Liver Cancer Therapeutics Market, Top Five European Countries, Treatment Usage Pattern (‘000), 2004-2011
Table 23: Liver Cancer Therapeutics Market, Top Five European Countries, Treatment Usage Pattern (‘000), 2011-2018
Table 24: Liver Cancer Therapeutics Market, Japan, Revenue ($m), 2004-2011
Table 25: Liver Cancer Therapeutics Market, Japan, Revenue Forecast ($m), 2011-2018
Table 26: Liver Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2004-2011
Table 27: Liver Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011-2018
Table 28: Liver Cancer Therapeutics Market, Japan, Treatment Usage Pattern (‘000), 2004-2011
Table 29: Liver Cancer Therapeutics Market, Japan, Treatment Usage Pattern (‘000), 2011-2018
Table 30: Liver Cancer Therapeutics Market, Global, Pipeline Products, by Stage of Development, 2012
Table 31: Liver Cancer Therapeutics Market, Global, Phase III Pipeline
Table 32: Liver Cancer Therapeutics Market, Global, Phase II/III Pipeline
Table 33: Liver Cancer Therapeutics Market, Global, Phase II Pipeline
Table 34: Liver Cancer Therapeutics Market, Global, Phase I/II Pipeline
Table 35: Liver Cancer Therapeutics Market, Global, Phase I Pipeline
Table 36: Liver Cancer Therapeutics Market, Global, Preclinical, 2012
Table 37: Liver Cancer Therapeutics Market, Global, Discovery, 2012
Table 38: Liver Cancer Therapeutics Market, Global, Bayer AG, Pharmaceutical Brands, 2012
Table 39: Liver Cancer Therapeutics Market, Global, Dainippon Sumitomo Pharma, Pharmaceutical Brands, 2012
Table 40: Liver Cancer Therapeutics Market, Global, Deals by Type of Agreement, 2007-2012
Table 41: Liver Cancer Therapeutics Market, Global, Deals by Geography, 2007-2012
Table 42: Liver Cancer Therapeutics Market, Global, Deals by Year, 2007-2012
Table 43: Liver Cancer Therapeutics Market, Global, Major M&A Deals, 2007-2012
Table 44: Liver Cancer Therapeutics Market, Global, Major Licensing Agreement Deals, 2007-2012
Table 45: Liver Cancer Therapeutics Market, Global, Major Co-Development Deals, 2007-2012

1.2 List of Figures

Figure 1: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, Treatment Options, 2012
Figure 2: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, General Treatment Algorithm
Figure 3: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, Stage I and II, Treatment Algorithm
Figure 4: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, Stage III and IV, Treatment Algorithm
Figure 5: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts ($m), 2004-2018
Figure 6: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts by Geography ($m), 2004-2018
Figure 7: Liver Cancer Therapeutics Market, Top Seven Markets, Annual Cost of Therapy ($), 2004-2018
Figure 8: Liver Cancer Therapeutics Market, Top Seven Markets, Treatment Usage Pattern (‘000), 2004-2018
Figure 9: Liver Cancer Therapeutics Market, Top Seven Markets, Drivers and Barriers, 2012
Figure 10: Liver Cancer Therapeutics Market, US, Revenue Forecasts ($m), 2004-2018
Figure 11: Liver Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2004-2018
Figure 12: Liver Cancer Therapeutics Market, US, Treatment Usage Pattern (‘000), 2004-2018
Figure 13: Liver Cancer Therapeutics Market, Top Five European Countries, Revenue Forecast ($m), 2004-2018
Figure 14: Liver Cancer Therapeutics Market, Top Five European Countries, Market Revenue ($m), 2004-2018
Figure 15: Liver Cancer Therapeutics Market, Top Five European Countries, Annual Cost of Therapy ($), 2004-2018
Figure 16: Liver Cancer Therapeutics Market, Top Five European Countries, Treatment Usage Pattern (‘000), 2004-2018
Figure 17: Liver Cancer Therapeutics Market, Japan, Revenue Forecast ($m), 2004-2018
Figure 18: Liver Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2004-2018
Figure 19: Liver Cancer Therapeutics Market, Japan, Treatment Usage Pattern (‘000), 2004-2018
Figure 20: Liver Cancer Therapeutics Market, Global, Pipeline Products, by Stage of Development, 2012
Figure 21: Liver Cancer Therapeutics Market, Global, Deals by Type of Agreement, 2007-2012
Figure 22: Liver Cancer Therapeutics Market, Global, Deals by Geography, 2007-2012
Figure 23: Liver Cancer Therapeutics Market, Global, Deals by Year, 2007-2012
Figure 24: GBI Research Market Forecasting Model

- Bayer
- Dainippon Sumitomo Pharma

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos